Pan-KRAS inhibition: unlocking broad-spectrum targeted therapy for KRAS-mutant cancers

Cancer Biology and Medicine 2026 Open access

Read full text
Authors: Juanjuan Feng, Xuanzheng Xiao, Zhengke Lian, Ao Zhang, Xiufeng Pang
DOI: 10.20892/j.issn.2095-3941.2025.0612
Cited by: 0

Abstract

KRAS is a critical proto-oncogene and molecular switch that is frequently mutated in human cancers. Oncogenic mutations, primarily at codons 12, 13, and 61, lock KRAS into a GTP-bound active state, thus resulting in constitutive signaling through downstream effectors such as RAF and phosphoinositide

Fields of Study & Subjects

Protein Kinase Regulation and GTPase Signaling Melanoma and MAPK Pathways Protein Tyrosine Phosphatases

Publication details

Journal / source
Cancer Biology and Medicine
Volume
23
Issue
2
Pages
1–7
Publication date
9 February 2026
Language
EN